These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 21677463)
1. Cross-trial comparisons in the oncology arena: when is this justified? Markman M Oncology; 2011; 80(3-4):151-2. PubMed ID: 21677463 [No Abstract] [Full Text] [Related]
2. Problems in antiemetic trial design and interpretation. Krasnow SH Oncology (Williston Park); 1989 Aug; 3(8 Suppl):5-10. PubMed ID: 2701576 [TBL] [Abstract][Full Text] [Related]
3. Clinical trial design in metastatic breast cancer: a commentary. Levine M Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523 [TBL] [Abstract][Full Text] [Related]
4. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Suman VJ; Dueck A; Sargent DJ Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764 [No Abstract] [Full Text] [Related]
5. [AUO guidelines. Practical information for planning and execution of studies 1993. Association of Urologic Oncology]. Urologe A; 1993 Mar; Suppl 1():S1-35. PubMed ID: 8493755 [No Abstract] [Full Text] [Related]
6. Cancer clinical trials: development and implementation. Vail DM Vet Clin North Am Small Anim Pract; 2007 Nov; 37(6):1033-57; v. PubMed ID: 17950881 [TBL] [Abstract][Full Text] [Related]
7. Measurement of success: parameters of efficacy. de Mulder PH Br J Cancer Suppl; 1992 Dec; 19():S68. PubMed ID: 1467205 [No Abstract] [Full Text] [Related]
8. European Commission considers revisions to clinical trials directive. Mason E J Natl Cancer Inst; 2010 Mar; 102(5):292-4, 297. PubMed ID: 20173121 [No Abstract] [Full Text] [Related]
9. Panel report. Interdisciplinary group on clinical trials (biostatistics). Zelen M Cancer Chemother Rep 3; 1973 Mar; 4(2):317-9. PubMed ID: 4580859 [No Abstract] [Full Text] [Related]
10. Antiemetic study design: a discussion of Dr Olver's paper. Groshen S Br J Cancer Suppl; 1992 Dec; 19():S35-7. PubMed ID: 1467199 [No Abstract] [Full Text] [Related]
11. Reader comments on complementary and alternative medicine programs. Lee CO Clin J Oncol Nurs; 2005 Oct; 9(5):510; author reply 510-1. PubMed ID: 16235577 [No Abstract] [Full Text] [Related]
12. Endpoints of clinical trials for muscle-invasive bladder cancer. Tannock IF Prog Clin Biol Res; 1990; 353():65-74. PubMed ID: 2217428 [No Abstract] [Full Text] [Related]
13. Response assessment in clinical trials: implications for sarcoma clinical trial design. Jaffe CC Oncologist; 2008; 13 Suppl 2():14-8. PubMed ID: 18434633 [TBL] [Abstract][Full Text] [Related]
14. Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease. Pocard M; Soria JC; Aldaz-Carroll L; Bellet D J Clin Oncol; 2010 Oct; 28(30):4551-3. PubMed ID: 20837954 [No Abstract] [Full Text] [Related]
18. American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 2. Walker K IDrugs; 2007 Aug; 10(8):517-9. PubMed ID: 17665321 [No Abstract] [Full Text] [Related]
19. Special feature: in quest of an effective antiemetic in cancer chemotherapy. Research with antiemetics for cancer chemotherapy: problems and possibilities. Maxwell MB Oncol Nurs Forum; 1982; 9(3):11-6. PubMed ID: 7050931 [No Abstract] [Full Text] [Related]
20. Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Michaelis LC; Ratain MJ Clin Cancer Res; 2007 Apr; 13(8):2400-5. PubMed ID: 17438099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]